Capricor Therapeutics CAPR Announces PositiveTopline Results from Pivotal Phase 3HOPE-3 Study of Deramiocel in DuchenneMuscular Dystrophy
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)
